(June 1, 2021 – Hong Kong) China Grand Pharmaceutical and Healthcare Holdings Limited (“GP (HK)” or the “Company”, together with its subsidiaries, the “Group”, stock code: 00512) is pleased to announce that in light of the Company’s strategies to pursue further technological innovation and internationalisation and to introduce fresh ideas with professional and international vision to the senior management team. From June 1, 2021, the Board has resolved to appoint Mr. Zhou Chao as the chief executive officer of the Company. Dr. Shao Yan has resigned as the chief executive officer of the Company, but will remain to be an executive Director with a strategic focus in business development and investment. Dr. Tang Wei Kun and Dr. Shi Lin have been appointed as executive Directors. Dr. Tang is also appointed as the chairman of the Board and a member of the remuneration committee of the Company. Mr. Liu Chengwei and Mr. Hu Bo they have ceased to be chairman and deputy chairman of the Board respectively due to their own decisions to devote more time to their personal engagements.
Mr. Zhou Chao (周超), aged 31, has been the executive deputy officer of the Company since April 2019, and is also a director of certain associated companies of the Group, including OncoSec Medical Inc., a company listed on NASDAQ in the United States (NASDAQ: ONCS). Prior to joining the Company, Mr. Zhou has been the legal manager, senior legal manager and business director of the department of legal security management of China Grand Enterprises Incorporation (a substantial shareholder of the Company). Mr. Zhou graduated from the Law School of Ocean University of China (中國海洋大學) in 2011, and obtained his master’s degree in international economic law from the University of International Business and Economics (對外經濟貿易大學) of China in 2013.
Dr. Tang Weikun (唐緯坤), aged 36, joined Grand Pharma (China) Co., Ltd. (a major subsidiary of the Group) (“Grand Pharma (China)”) in 2012 and worked for several companies of the Group. He has been the assistant of the president of Grand Pharma (China) since April 2019, and was appointed as the president of Grand Pharma (China) with effect from 1 June 2021. Dr. Tang has overall responsible for the operation of Grand Pharma (China). Dr. Tang completed his life science and technology undergraduate education at Wuhan University in 2007, and obtained his doctoral degree in microbiology from the College of Life Sciences, Wuhan University in 2012.
Dr. Shi Lin (史琳), aged 57, joined the Group in 2019 and is currently the deputy president and chief pharmaceutical officer of Grand Pharma (China). Before joining the Group, she had been the EU Regulatory Leader in Global Regulatory Affairs (GRA) Neuroscience of Janssen R&D in Belgium. Dr. Shi has over 20 years of clinical and research experience in the pharmaceutical industry, with significant experience working with global multifunctional matrix teams to drive forward complex projects. She led various applications for clinical trials (Clinical Trial Applications (CTA) and Investigational New Drug Applications (IND)) in different countries in Europe and the United States, particularly in relation to strategic assessments in first clinical trials and innovative research paths. Dr. Shi obtained her doctoral degree in medical science from Vrije Universiteit Brussel in 2005. She has been appointed as professor and visiting fellow in various universities, an expert engaged under the Help Our Motherland through Elite Intellectual Resources from Overseas Programme* (海外智力為國服務行動計劃) established by the China Association for Science and Technology (中國科學技術協會) (2015 – 2020), a visiting professor of Tongji Medical College affiliated to Huazhong University of Science and Technology (華中科技大學同濟醫學院) in Wuhan and the Third Affiliated Hospital of the Third Military Medical University* (第三軍醫大學第三附屬醫院) in Chongqing. Dr. Shi was awarded as “2014 Top Ten Chinese Technology Leaders in Europe” (2014度歐洲華人10大科技領軍人才*) by the Federation of Chinese Professional Associations in Europe (全歐華人專業協會聯合會*).
The Board of China Grand Pharmaceutical and Healthcare Holdings Limited, commented, “The Board would like to take this opportunity to express its sincere gratitude to Dr. Shao for his valuable contributions to the Company during his tenure of office as the chief executive officer of the Company, and Mr. Liu Chengwei and Mr. Hu Bo for their contributions to the Company during their tenure of office. The Board would like to express its warm welcome to new appointees for their new positions in the Company, who will inject new impetus into the Group and help to pursue further technological innovation and internationalisation and to introduce fresh ideas with professional and international vision to the senior management team. We believe new appointees will continue to lead the Group to become a leading technological innovation international pharmaceutical company in China and even the world, providing patients with more diverse treatment options in the globe and creating greater returns for shareholders.”
